Logo
x

Search

Subscribe Now

Bridgebio Pharma

BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan

BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan

  • February 7, 2024
BridgeBio Pharma Initiates P-III Study (CALIBRATE) of Encaleret for Autosomal Dominant Hypocalcemia Type 1

BridgeBio Pharma Initiates P-III Study (CALIBRATE) of Encaleret for Autosomal Dominant Hypocalcemia Type 1

  • December 23, 2022
Bridgebio Pharma Presents 12-Month P-II Study Results of BBP-418 for Limb-Girdle Muscular Dystrophy Type 2i at WMS 2022

Bridgebio Pharma Presents 12-Month P-II Study Results of BBP-418 for Limb-Girdle Muscular Dystrophy Type 2i at WMS 2022

  • October 17, 2022
BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022

BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022

  • October 14, 2022
BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Cancer

BridgeBio Pharma Reports First Patient Dosing in P-I/II Trial for BBP-398 + Lumakras (sotorasib) to Treat Non-Small Cell Lung Canc...

  • October 12, 2022
BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat MoCD Type A

BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat Mo...

  • September 21, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.